SEC Form 4 · accession 0001209191-17-031664
Atara Biotherapeutics, Inc. · ATRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Derrell Porter
Officer — SVP, Head of Global Commercial
Period of report
May 10, 2017
Accepted (ET)
May 11, 2017 · 7:40 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001604464
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $14.30 | May 10, 2017 | A | 130,000 | A | — | May 10, 2024 | Common Stock | 130,000 | 130,000 | D |
Explanation of responses
- F125% of the shares subject to the option vest and become exercisable on May 10, 2018 and 1/48th of the shares subject to the stock option vest and become exercisable each full month thereafter.